Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- DKK | -.--% | -.--% | -0,50% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stacy Wheeler
COO | Chief Operating Officer | - | 01-03-16 |
Chief Tech/Sci/R&D Officer | - | 13-09-17 | |
Lionel Rostaing
PRN | Corporate Officer/Principal | - | - |
Josep Grinyo
PRN | Corporate Officer/Principal | - | - |
Noel Barnard
LAW | General Counsel | - | 01-03-16 |
Mark Hensley
PRN | Corporate Officer/Principal | - | 01-04-16 |
Rita L. Mannella
HRO | Human Resources Officer | - | 01-01-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 739 741 590 | 173 932 405 ( 9,998 %) | 0 | 9,998 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Asahi Kasei Corp., Veloxis Pharmaceuticals, Inc. manufactures pharmaceuticals for kidney transplant patients. The private company is based in Edison, NJ. |
Pharmaceuticals: Major
|
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,50% | 1,64 mld. | |
+5,31% | 70,44 mld. | |
+10,97% | 8,94 mld. | |
-16,83% | 4,75 mld. | |
+43,48% | 4,5 mld. | |
+3,20% | 3,85 mld. | |
-21,36% | 2,34 mld. | |
-29,67% | 2,2 mld. | |
+8,38% | 1,96 mld. | |
+3,90% | 1,65 mld. |
- Beurs
- Aandelen
- Koers VELO
- Onderneming Veloxis Pharmaceuticals A/S